Insmed Incorporated (LON:0JAV)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 25.81B |
| Revenue (ttm) | 290.58M |
| Net Income (ttm) | -754.97M |
| Shares Out | n/a |
| EPS (ttm) | -4.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 208 |
| Average Volume | 765 |
| Open | 160.00 |
| Previous Close | 165.26 |
| Day's Range | 160.00 - 164.29 |
| 52-Week Range | 61.28 - 167.98 |
| Beta | 1.03 |
| RSI | 71.71 |
| Earnings Date | Oct 30, 2025 |
About Insmed
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 c... [Read more]
Financial Performance
In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.
Financial numbers in USD Financial StatementsNews
INSM Quantitative Stock Analysis - Benjamin Graham
Below is Validea's guru fundamental report for INSMED INC (INSM). Of the 22 guru strategies we follow, INSM rates highest using our Value Investor model based on the published strategy of Benjamin Gra...
JPMorgan Chase & Co. Expands Holdings in Insmed Inc. with Significant Share Acquisition
JPMorgan Chase & Co. Expands Holdings in Insmed Inc. with Significant Share Acquisition
Insmed Incorporated (INSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Guggenheim Raises Insmed (INSM) Price Target to $172 | INSM Stock News
Guggenheim Raises Insmed (INSM) Price Target to $172 | INSM Stock News
3 Stocks To Consider After Google's Favorable Anti-Trust Ruling
A federal judge's decision this week, allowing Google (NASDAQ: GOOG) to maintain its Chrome browser and dominant search business, has Wall Street breathing a sigh of relief. The ruling removes the ne...
Insmed Incorporated (INSM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Insmed Reports Inducement Grants Under Nasdaq Rule | INSM stock news
Insmed Reports Inducement Grants Under Nasdaq Rule | INSM stock news
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Sept. 5, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor...
Wells Fargo Raises INSM Price Target to $171, Maintains Overweight Rating | INSM Stock News
Wells Fargo Raises INSM Price Target to $171, Maintains Overweight Rating | INSM Stock News
Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It
United Therapeutics stock catapulted Tuesday, pulling shares of rivals Insmed and Liquidia higher, on positive test results in IPF.
Insmed (INSM) Gains FDA Orphan Status for Duchenne Muscular Dystrophy Treatment
Insmed (INSM) Gains FDA Orphan Status for Duchenne Muscular Dystrophy Treatment
Insmed To Present at September Investor Conferences
BRIDGEWATER, N.J. , Aug. 21, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor...
Lung Disease-Focused Insmed 'Must-Own' Name For Investors
William Blair initiated coverage on Insmed Incorporated (NASDAQ: INSM), citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation. “While acknowledg...
Lung Disease-Focused Insmed 'Must-Own' Name For Investors
William Blair initiated coverage on Insmed Incorporated INSM, citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.
Josh Brown's Best Stocks in the Market: Insmed
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail his latest addition to his 'Best Stocks in the Marlet,' Insmed.
Josh Brown's Best Stocks in the Market: Insmed
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail his latest addition to his 'Best Stocks in the Marlet,' Insmed.
Insmed CEO on what's next for company after FDA greenlights lung disease drug
Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for for the stock.
Insmed downgraded at Morgan Stanley despite FDA nod for lung therapy
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
The FDA approves Insmed's Brinsupri for NCFB, ... Full story available on Benzinga.com
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated's INSM Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis ...
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval
Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a devastating lung condition.
Insmed wins FDA approval for lung disorder therapy Brinsupri
Insmed (INSM) stock rises as the FDA greenlights its lung disorder drug Brinsupri for patients with on-cystic fibrosis bronchiectasis. Read more here.
US FDA approves Insmed's lung disease drug
The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition.
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10 mg and 25 mg Doses App...
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10 mg and 25 mg Doses Ap...